Skip to content

ANGiographic Evaluation of Left Main Coronary Artery INtErvention

ANGiographic Evaluation of Left Main Coronary Artery INtErvention

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04604197
Acronym
ANGELINE
Enrollment
400
Registered
2020-10-27
Start date
2021-04-16
Completion date
2026-04-01
Last updated
2026-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Occlusion, Left Main Coronary Artery Disease

Keywords

Angiography

Brief summary

To assess if an angiographic follow-up at 6 months after Percutaneous Coronary Intervention in Left Main Coronary Artery Disease decrease the composite objective of death, myocardial infarction, and stroke at 36 months.

Detailed description

Percutaneous coronary intervention (PCI) with drug-eluting stents in left main (LM) disease has demonstrated similar results than surgical revascularization in patients with SYNTAX score \< 33, being the main drawback of PCI a higher rate of new revascularization. A small study found a reduction in the composite end-point of cardiac death, myocardial infarction and urgent revascularization with a routine angiographic follow-up. The investigators have designed a prospective, randomized, controlled, two-arm multicenter study in patients aged 18-85 with LM disease and SYNTAX score \<33 and in cases ≥ 33 based on the Heart Team decision to assess the benefit of a routine angiographic follow-up 6 months after LM stenting. After the index procedure and before hospital discharge the patient will be randomized to routine invasive angiographic follow-up at 6 months plus clinical follow-up at 6 months, 1, 2 and 3 years vs. the control arm, which would be followed clinically at 6 months, 1, 2 and 3 years. Based on our calculations, an adequately powered trial would require 1009 patients per arm but due to the uncertainty of the results and the current economical restrictions we have designed a pilot study in 400 patients to find out the convenience of an adequately powered trial. All the lesions should be treated with an everolimus eluting stent with permanent fluoropolymer. It will be desirable to achieve complete revascularization and it will be highly recommended to perform the procedures guided with an intravascular image technique (OCT or IVUS (IntraVascular UltraSound) according to operator´s criteria). The main outcome will be death, myocardial infarction and cerebrovascular accident at 3 years. The initial percutaneous technique and the decision about the convenience and way of revascularization in case of restenosis in the follow-up will be left at the operator´s discretion, according in the most adequate way to the current guidelines. Nonetheless, the investigators are strongly encouraged to rely on intravascular techniques, based on either imaging or physiology. In those cases with in-stent hyperplasia with doubts about possible restenosis, FFR and RFR (Resting full-cycle ratio) will be performed, with low threshold to achieve a high rate of ruling out the restenosis.

Interventions

OTHERAngiography and Clinical Follow up

Angiography and Clinical Follow up

Clinical Follow up

Sponsors

Fundación EPIC
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Age: 18- 85 years at the date of the PCI. * With PCI for presenting de novo lesions in the Left Main Artery by implanting a cobalt-chrome stent with everolimus-eluting fluoropolymer. * Informed consent signed.

Exclusion criteria

* Refusal to participate in the study. * Patients with left main disease who have been admitted with STEMI and have undergone primary angioplasty in a culprit lesion different than the left main. The left main lesion has been treated as a stage procedure and discharged with left ventricular ejection fraction \< 35 %. * Previous coronary surgery. * Creatinine clearance \<40 ml / min. * Contraindication for double antiaggregation after PCI. * Patients life expectancy \<36 months. * Included in other studies or clinical trials. * Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frameDescription
Composite endpoint: defined as : death, myocardial infarction, and stroke.36 monthsComposite endpoint: defined as : death, myocardial infarction, and stroke.

Secondary

MeasureTime frameDescription
All Death36 monthsOccurrence of Death
Cardiac Death36 monthsOccurrence of Cardiac Death
Myocardial Infarction36 monthsOccurrence of Myocardial Infarction
Stroke36 monthsOccurrence of Stroke
Stent thrombosis (ARC definite/probable)36 monthsOccurrence of thrombosis (ARC definite/probable)
Major bleeding event (BARC type 2-5)36 monthsOccurrence of Major bleeding event (BARC type 2-5)
Target Vessel revascularization.36 monthsOccurrence of Target Vessel revascularization.
Revascularization by CABG ( Coronary Artery Bypass Grafting) or PCI (Percutaneous Coronary Intervention)36 monthsOccurrence of New revascularization by CABG or PCI

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026